vs

Side-by-side financial comparison of Aether Holdings, Inc. (ATHR) and Keros Therapeutics, Inc. (KROS). Click either name above to swap in a different company.

Keros Therapeutics, Inc. is the larger business by last-quarter revenue ($385.0K vs $338.8K, roughly 1.1× Aether Holdings, Inc.). On growth, Aether Holdings, Inc. posted the faster year-over-year revenue change (-0.9% vs -87.3%). Keros Therapeutics, Inc. produced more free cash flow last quarter ($106.0M vs $-2.2M).

Aether Industries Limited is an Indian chemical manufacturing company based in Surat, Gujarat. The company specializes in producing advanced intermediates and specialty chemicals for various industries, including pharmaceuticals, agrochemicals, material sciences, and oil and gas.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for hematological disorders, musculoskeletal diseases and anemia, serving underserved patient groups with unmet medical needs from its core U.S. base.

ATHR vs KROS — Head-to-Head

Bigger by revenue
KROS
KROS
1.1× larger
KROS
$385.0K
$338.8K
ATHR
Growing faster (revenue YoY)
ATHR
ATHR
+86.4% gap
ATHR
-0.9%
-87.3%
KROS
More free cash flow
KROS
KROS
$108.1M more FCF
KROS
$106.0M
$-2.2M
ATHR

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ATHR
ATHR
KROS
KROS
Revenue
$338.8K
$385.0K
Net Profit
$-1.3M
Gross Margin
80.4%
Operating Margin
-382.9%
Net Margin
-382.9%
Revenue YoY
-0.9%
-87.3%
Net Profit YoY
-232.5%
49.0%
EPS (diluted)
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATHR
ATHR
KROS
KROS
Q4 25
$338.8K
$385.0K
Q3 25
$14.3M
Q2 25
$342.4K
$18.2M
Q1 25
$341.9K
$211.2M
Q3 24
$388.0K
Q2 24
$37.0K
Q1 24
$83.0K
Q3 23
$8.0K
Net Profit
ATHR
ATHR
KROS
KROS
Q4 25
$-1.3M
Q3 25
$-7.3M
Q2 25
$-1.0M
$-30.7M
Q1 25
$-427.4K
$148.5M
Q3 24
$-53.0M
Q2 24
$-45.3M
Q1 24
$-43.1M
Q3 23
$-39.4M
Gross Margin
ATHR
ATHR
KROS
KROS
Q4 25
80.4%
Q3 25
Q2 25
69.9%
Q1 25
67.9%
Q3 24
Q2 24
Q1 24
Q3 23
Operating Margin
ATHR
ATHR
KROS
KROS
Q4 25
-382.9%
Q3 25
-107.9%
Q2 25
-293.7%
-219.2%
Q1 25
-112.6%
72.0%
Q3 24
-15117.8%
Q2 24
-136321.6%
Q1 24
-58413.3%
Q3 23
-541000.0%
Net Margin
ATHR
ATHR
KROS
KROS
Q4 25
-382.9%
Q3 25
-51.0%
Q2 25
-293.7%
-169.0%
Q1 25
-125.0%
70.3%
Q3 24
-13648.5%
Q2 24
-122316.2%
Q1 24
-51944.6%
Q3 23
-493000.0%
EPS (diluted)
ATHR
ATHR
KROS
KROS
Q4 25
$-0.11
Q3 25
$-0.18
Q2 25
$-0.08
$-0.76
Q1 25
$-0.04
$3.62
Q3 24
$-1.41
Q2 24
$-1.25
Q1 24
$-1.21
Q3 23
$-1.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATHR
ATHR
KROS
KROS
Cash + ST InvestmentsLiquidity on hand
$263.3K
$287.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$3.4M
$303.1M
Total Assets
$4.0M
$338.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATHR
ATHR
KROS
KROS
Q4 25
$263.3K
$287.4M
Q3 25
$693.5M
Q2 25
$187.4K
$690.2M
Q1 25
$179.2K
$720.5M
Q3 24
$530.7M
Q2 24
$405.9M
Q1 24
$442.4M
Q3 23
$287.9M
Stockholders' Equity
ATHR
ATHR
KROS
KROS
Q4 25
$3.4M
$303.1M
Q3 25
$703.6M
Q2 25
$5.9M
$706.7M
Q1 25
$-596.3K
$728.9M
Q3 24
$532.8M
Q2 24
$420.9M
Q1 24
$453.9M
Q3 23
$295.8M
Total Assets
ATHR
ATHR
KROS
KROS
Q4 25
$4.0M
$338.0M
Q3 25
$742.8M
Q2 25
$6.5M
$757.2M
Q1 25
$367.8K
$784.6M
Q3 24
$579.3M
Q2 24
$455.0M
Q1 24
$485.8M
Q3 23
$326.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATHR
ATHR
KROS
KROS
Operating Cash FlowLast quarter
$-1.0M
$107.5M
Free Cash FlowOCF − Capex
$-2.2M
$106.0M
FCF MarginFCF / Revenue
-642.5%
27520.5%
Capex IntensityCapex / Revenue
344.9%
402.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$239.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATHR
ATHR
KROS
KROS
Q4 25
$-1.0M
$107.5M
Q3 25
$3.2M
Q2 25
$-2.0M
$-29.6M
Q1 25
$161.2M
Q3 24
$-30.5M
Q2 24
$-39.8M
Q1 24
$-44.6M
Q3 23
$-34.0M
Free Cash Flow
ATHR
ATHR
KROS
KROS
Q4 25
$-2.2M
$106.0M
Q3 25
$3.1M
Q2 25
$-30.3M
Q1 25
$160.6M
Q3 24
$-30.9M
Q2 24
$-40.1M
Q1 24
$-45.5M
Q3 23
$-34.5M
FCF Margin
ATHR
ATHR
KROS
KROS
Q4 25
-642.5%
27520.5%
Q3 25
21.9%
Q2 25
-167.0%
Q1 25
76.0%
Q3 24
-7960.3%
Q2 24
-108408.1%
Q1 24
-54826.5%
Q3 23
-431650.0%
Capex Intensity
ATHR
ATHR
KROS
KROS
Q4 25
344.9%
402.9%
Q3 25
0.9%
Q2 25
4.0%
Q1 25
0.3%
Q3 24
99.5%
Q2 24
837.8%
Q1 24
1139.8%
Q3 23
6875.0%
Cash Conversion
ATHR
ATHR
KROS
KROS
Q4 25
Q3 25
Q2 25
Q1 25
1.09×
Q3 24
Q2 24
Q1 24
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons